Objective:To investigate the effects of Xinjikang on the left ventricular hypertrophy remodeling and myocardial activity in hypertension.Methods:Sixty Wistar rats were randomly divided into four groups.The pressure-lo...Objective:To investigate the effects of Xinjikang on the left ventricular hypertrophy remodeling and myocardial activity in hypertension.Methods:Sixty Wistar rats were randomly divided into four groups.The pressure-loaded left ventricular hypertrophy model was established with abdominal aorta ligation method.Rats in A and B groups were intragastrically administered with physiological saline,while C and D groups were administered with Xinjikang and metoprolol,respectively.The changes in blood pressure.E/A ratio,myocardial pathological morphology,myocardial lipoperoxides and superoxide dismustase activity in four groups were observed and compared before and after treatment.Results:There were statistically significant differences in E/A ratio between C group after treatment and model group(P<0.05).while no difference was observed between A and D groups(P>0.05);after treatment the myocardial lipoperoxides and superoxide dismustase contents in C and D groups were improved significantly compared with model group(P<0.05).Conclusions:Xinjikang can improve myocardial injury,restore myocardial parenchyma and myocardial interstitial remodeling functions in hypertensive rats with the left ventricular hypertrophy.展开更多
目的观察灯盏细辛注射液联合心肌康颗粒治疗病毒性心肌炎的临床疗效。方法选取2011年7月—2017年2月在湖北医药学院附属人民医院诊治的病毒性心肌炎患者128例为研究对象,随机将入组患者分为对照组和治疗组,每组各64例。对照组口服心肌...目的观察灯盏细辛注射液联合心肌康颗粒治疗病毒性心肌炎的临床疗效。方法选取2011年7月—2017年2月在湖北医药学院附属人民医院诊治的病毒性心肌炎患者128例为研究对象,随机将入组患者分为对照组和治疗组,每组各64例。对照组口服心肌康颗粒,1袋/次,2次/d;治疗组在对照组治疗的基础上静脉滴注注射用灯盏细辛注射液,30 m L加入5%葡萄糖溶液250 m L,1次/d。两组患者均连续治疗1个月。观察两组患者临床疗效和心电图疗效,比较治疗前后两组患者心肌酶谱和血清炎症因子水平。结果治疗后,对照组患者临床总有效率分别为73.44%、90.63%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者磷酸肌酸激酶(CK)、心肌肌钙蛋白Ⅰ(c Tn I)、肌酸激酶同工酶(CK-MB)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组心肌酶谱水平显著低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、超敏C反应蛋白(hs-CRP)水平均明显下降,超氧化物歧化酶(SOD)水平明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组血清炎性因子水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论灯盏细辛注射液联合心肌康颗粒具有较好的临床疗效,能够改善病毒性心肌炎心肌酶谱,抑制炎症因子表达,具有一定的临床推广价值。展开更多
文摘Objective:To investigate the effects of Xinjikang on the left ventricular hypertrophy remodeling and myocardial activity in hypertension.Methods:Sixty Wistar rats were randomly divided into four groups.The pressure-loaded left ventricular hypertrophy model was established with abdominal aorta ligation method.Rats in A and B groups were intragastrically administered with physiological saline,while C and D groups were administered with Xinjikang and metoprolol,respectively.The changes in blood pressure.E/A ratio,myocardial pathological morphology,myocardial lipoperoxides and superoxide dismustase activity in four groups were observed and compared before and after treatment.Results:There were statistically significant differences in E/A ratio between C group after treatment and model group(P<0.05).while no difference was observed between A and D groups(P>0.05);after treatment the myocardial lipoperoxides and superoxide dismustase contents in C and D groups were improved significantly compared with model group(P<0.05).Conclusions:Xinjikang can improve myocardial injury,restore myocardial parenchyma and myocardial interstitial remodeling functions in hypertensive rats with the left ventricular hypertrophy.
文摘目的观察灯盏细辛注射液联合心肌康颗粒治疗病毒性心肌炎的临床疗效。方法选取2011年7月—2017年2月在湖北医药学院附属人民医院诊治的病毒性心肌炎患者128例为研究对象,随机将入组患者分为对照组和治疗组,每组各64例。对照组口服心肌康颗粒,1袋/次,2次/d;治疗组在对照组治疗的基础上静脉滴注注射用灯盏细辛注射液,30 m L加入5%葡萄糖溶液250 m L,1次/d。两组患者均连续治疗1个月。观察两组患者临床疗效和心电图疗效,比较治疗前后两组患者心肌酶谱和血清炎症因子水平。结果治疗后,对照组患者临床总有效率分别为73.44%、90.63%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者磷酸肌酸激酶(CK)、心肌肌钙蛋白Ⅰ(c Tn I)、肌酸激酶同工酶(CK-MB)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组心肌酶谱水平显著低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、超敏C反应蛋白(hs-CRP)水平均明显下降,超氧化物歧化酶(SOD)水平明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组血清炎性因子水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论灯盏细辛注射液联合心肌康颗粒具有较好的临床疗效,能够改善病毒性心肌炎心肌酶谱,抑制炎症因子表达,具有一定的临床推广价值。